This content is from: Premium

ValueAct Gets Boost from Valeant Deal

The activist investment firm is the third largest shareholder in the pharmaceutical company, whose shares surged on news it was acquiring Bausch & Lomb.

Valeant Pharmaceuticals International’s acquisition of Bausch & Lomb for $8.7 billion in cash is a big boon for a handful of savvy hedge fund managers, especially Jeffrey Ubben. Ubben runs the ValueAct Holdings hedge fund out of ValueAct Capital, his San Francisco–based investment firm. ValueAct is the third-largest investor in Valeant,

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content